Literature DB >> 10519943

Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations.

F P Kroon1, J T van Dissel, E Ravensbergen, P H Nibbering, R van Furth.   

Abstract

We studied the production of IgG antibodies against eight pneumococcal polysaccharide serotypes (PPS) 1, 4, 6B, 9V, 14, 18C, 19F and 23F after vaccination of 50 HIV-infected adults with 23-valent Pneumovax((R))23 and the course of the antibodies against four PPS during the following years. Mean antibody concentrations against PPS 18C, 19F and 23F were sigificantly lower in the patients with CD4(+)-lymphocyte counts <200x10(6)/l than in healthy controls; mean antibody concentrations against PPS 1, 4, 9V, 6B and 14 were similar in HIV-infected individuals and controls. Although it has been assumed that polysaccharides induce a T-cell-independent immune response, our results indicate that some PPS are T-cell-independent type 2 antigens. The rates of decline of mean antibody concentrations in HIV-infected individuals and in healthy controls were similar during 5 y after vaccination. However, as a consequence of the low postvaccination antibody concentrations against several PPS, within 3 y after vaccination most HIV-infected individuals had antibody concentrations below the level which is assumed to be required for protection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10519943     DOI: 10.1016/s0264-410x(99)00240-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.

Authors:  Haijun Tian; Avi Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

2.  A population-based analysis of pneumococcal disease mortality in California, 1989-1998.

Authors:  Matthew D Redelings; Frank Sorvillo; Paul Simon
Journal:  Public Health Rep       Date:  2005 Mar-Apr       Impact factor: 2.792

Review 3.  Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.

Authors:  Kuan-Yeh Lee; Mao-Song Tsai; Kuang-Che Kuo; Jen-Chih Tsai; Hsin-Yun Sun; Aristine C Cheng; Sui-Yuan Chang; Chen-Hsiang Lee; Chien-Ching Hung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Pneumococcal vaccines: understanding centers for disease control and prevention recommendations.

Authors:  Mehdi Mirsaeidi; Dean E Schraufnagel
Journal:  Ann Am Thorac Soc       Date:  2014-07

5.  Impact of human immunodeficiency virus infection on Streptococcus pneumoniae colonization and seroepidemiology among Zambian women.

Authors:  C J Gill; V Mwanakasale; M P Fox; R Chilengi; M Tembo; M Nsofwa; V Chalwe; L Mwananyanda; D Mukwamataba; B Malilwe; D Champo; W B Macleod; D M Thea; D H Hamer
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

6.  Evidence of early B-cell dysregulation in simian immunodeficiency virus infection: rapid depletion of naïve and memory B-cell subsets with delayed reconstitution of the naïve B-cell population.

Authors:  David Kuhrt; Seth A Faith; Amanda Leone; Mukta Rohankedkar; Donald L Sodora; Louis J Picker; Kelly Stefano Cole
Journal:  J Virol       Date:  2009-12-23       Impact factor: 5.103

Review 7.  An overview of vaccinations in HIV.

Authors:  Edgar Turner Overton
Journal:  Curr HIV/AIDS Rep       Date:  2007-08       Impact factor: 5.495

Review 8.  Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.

Authors:  Marta C Nunes; Shabir A Madhi
Journal:  Hum Vaccin Immunother       Date:  2012-02-01       Impact factor: 3.452

9.  Sublingual Bacterial Vaccination Reduces Recurrent Infections in Patients With Autoimmune Diseases Under Immunosuppressant Treatment.

Authors:  Silvia Sánchez-Ramón; Lidia Fernández-Paredes; Paula Saz-Leal; Carmen M Diez-Rivero; Juliana Ochoa-Grullón; Concepción Morado; Pilar Macarrón; Cristina Martínez; Virginia Villaverde; Antonia Rodríguez de la Peña; Laura Conejero; Keyla Hernández-Llano; Gustavo Cordero; Miguel Fernández-Arquero; Benjamin Fernández- Gutierrez; Gloria Candelas
Journal:  Front Immunol       Date:  2021-06-04       Impact factor: 7.561

10.  Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs.

Authors:  Meliha Crnkic Kapetanovic; Tore Saxne; Lennart Truedsson; Pierre Geborek
Journal:  Arthritis Res Ther       Date:  2013-01-04       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.